SEC Form 4 · accession 0001209191-18-063774
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil F. McFarlane
Officer — Chief Operating Officer
Period of report
Dec 18, 2018
Accepted (ET)
Dec 20, 2018 · 7:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Dec 18, 2018 | A | 11,125 | $0.00 | A | 40,081 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On May 17, 2017, the reporting person was granted performance restricted stock units (PRSUs) covering 22,250 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On December 18, 2018, a portion of the PRSUs vested upon the Issuer's confirmation that the Phase 3 FORT study of fosmetpantotenate in PKAN had fully enrolled.
- F2Includes 480 shares of the Issuer's common stock acquired by the reporting person on November 30, 2018 pursuant to an employee stock purchase program.